Correlation Between Body Mass Index and Leucopenia After Administration of Valganciclovir for Cytomegalovirus Infection in Chinese Cardiac Recipients

概要

論文の詳細を見る
Background Valganciclovir (VGC) has recently been proved efficacious for the prophylaxis and treatment of cytomegalovirus (CMV) infection in transplant recipients. Leucopenia is a troublesome complication of VGC but the possible risk factors are unknown. Methods and Results Once a cardiac recipient's quantitative real-time CMV-polymerase chain reaction result showed positive, VGC was administered for 3 months. The 61 cardiac recipients enrolled in this study were divided into 2 groups: non-leucopenia group (n=29) and leucopenia group (n=32). The white blood cell (WBC) counts in the leucopenia group dropped approximately 55.6% in the first month after VGC therapy (pre-VGC WBC count: 5,544cells/mm^3 vs post-VGC WBC count: 2,460cells/mm^3, p<0.0001). The most significant difference between the 2 groups was body mass index (BMI, 23.04 vs 25.84, p=0.008), which was the impact factor of VGC-induced leucopenia. Conclusion Severe leucopenia may develop after VGC therapy in Chinese cardiac recipients, especially those with lower BMI.
社団法人日本循環器学会の論文
2007-05-20